כל המחקרים
גיוסתצפיתי

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

This study aims to investigate a drug called Zn-DDC, also known as Imuthiol, for treating multiple myeloma and other blood cancers. Previous studies suggest Imuthiol is effective against cancer stem cells and has a good safety record. The goal is to see how Imuthiol, by itself and in combination with existing drugs like Lenalidomide (Revlimid) and Pomalidomide (Pomalyst), affects cancer cells in laboratory settings. Modern cancer treatments are improving outcomes but can be very expensive. Researchers hope that Imuthiol could provide an affordable and effective treatment, potentially in combination with other drugs. This initial laboratory work will help determine if these drugs are promising enough to move into trials with patients in the future, with the aim of quickly developing new treatments for blood cancers.

במבט חטוף

סטטוס
גיוס
נותן חסות
The Royal Wolverhampton Hospitals NHS Trust
יעד הרשמה
70
התחל
22 Oct 2021
השלמה משוערת
01 דצמבר 2027

על מה המחקר הזה?

This research is looking for new ways to treat multiple myeloma and other blood cancers. These conditions can be very challenging, and while new treatments have emerged, they often come with significant costs. This study is focusing on a drug called Zn-DDC, which you might also hear referred to as Imuthiol. Early studies have suggested that Imuthiol is good at targeting and getting rid of specific cancer cells known as cancer stem cells, and it has been used safely in previous human trials when given intravenously (into a vein).

The researchers want to explore if Imuthiol, either by itself or combined with other drugs you might be familiar with, like Lenalidomide (Revlimid) and Pomalidomide (Pomalyst), could be an effective and affordable treatment option. Before these drugs can be tested in patients, it's crucial to understand how they work at a cellular level. Therefore, this study will take place in a laboratory, where scientists will examine how cancer cells react to these different drug combinations.

The main goal is to see if these drugs can effectively control or kill cancer cells in a dish. If the results are promising, it could pave the way for faster development of new, effective, and potentially more affordable treatments for people with blood cancers in the future. This initial step is vital for guiding future decisions about which drug combinations to take forward for clinical trials with patients.

נקודות עיקריות

  • Exploring new, potentially affordable treatments for multiple myeloma and other blood cancers.
  • Investigating drug Zn-DDC (Imuthiol) alone and in combination with existing drugs.
  • This is a laboratory study, not a patient treatment trial.
  • Participation involves donating a small additional bone marrow sample during a routine procedure.
  • Aims to pave the way for future clinical trials and better patient outcomes.

מי עשוי להיות זכאי?

To be considered for this study, you would need to be an adult (age 18 or older) who has been diagnosed with a blood cancer, such as multiple myeloma or acute leukaemia.

Crucially, you must also be willing and able to understand the study information and provide your agreement to take part. This process is called giving ‘informed consent’.

If you are pregnant, you would not be able to participate in this study.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. האם אתה בן 18 או יותר?
  2. Have you been diagnosed with multiple myeloma or another blood cancer (like acute leukaemia)?
  3. Are you able and willing to understand information about the study and give your consent to participate?
  4. Are you not pregnant?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If you are eligible and agree to take part, your involvement would be straightforward and integrated into your routine care. You would be asked to donate a small extra amount (2-3ml) of bone marrow sample. This sample would be collected at the same time you are already having a bone marrow aspirate as part of your standard medical tests for diagnosis or when your condition is being re-assessed (at relapse).

This extra sample would then be sent to the University of Wolverhampton for laboratory analysis. The research team would also collect some routine information from your medical records, such as the date you were diagnosed, the stage of your disease, your age, sex, and any previous treatments you’ve had. This clinical information will be kept securely at The Royal Wolverhampton NHS Trust until your sample has been analysed. Once the laboratory results are ready, this clinical information will be shared to help the researchers understand how the lab findings relate to your condition. There are no additional visits, medication, or follow-up appointments required specifically for this study.

סיכונים ותועלות פוטנציאליים

There are no direct personal benefits for patients taking part in this specific laboratory study, as the research is focused on understanding how drugs work on samples, not on providing treatment. The main benefit is to advance our understanding of multiple myeloma and other blood cancers, potentially leading to better, more affordable treatments for future patients. The risks associated with participation are minimal, as your involvement only requires an additional small bone marrow sample taken during a procedure you are already undergoing as part of your standard care. The main risk is the very slight additional discomfort or bruising at the bone marrow collection site. You have the full right to withdraw your consent and participation at any time without affecting your medical care.

מיקומים (1)

  • The Royal Wolverhampton NHS Trust
    מיקוד מאומת
    Wolverhampton, United Kingdom· גיוס

שאלות נפוצות

What is Zn-DDC (Imuthiol)?

It's a drug being studied for blood cancers, which has shown promise in fighting cancer stem cells and has been safely used in past trials.

Will I receive treatment as part of this study?

No, this is a lab-based study using donated samples, not a treatment trial for patients.

What is the purpose of collecting bone marrow samples?

The samples help researchers understand how cancer cells react to different drugs in a laboratory setting before testing them in people.

Is my personal information kept private?

Yes, your clinical information will be kept confidential and managed securely by the hospital and researchers, only being used for study purposes.

מה קורה אם אני משנה את דעתי לגבי ההשתתפות?

You are free to withdraw from the study at any time without it affecting your medical care or treatment.

כיצד לגלות עוד

Supratik Basu

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

מעוניינים להשתתף?

רשום את התעניינותך

שתף את הפרטים שלך וצוות המחקר עבור "Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple M…" ייצרו איתך קשר אם אתה עשוי להיות זכאי. תמיד התייעץ עם הרופא שלך לפני שאתה מסכים להשתתף.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.